Upcoming event
EAU UROonco: A meeting steered by the EAU Section of Oncological Urology (ESOU)
Back

Tags

Article of the Month, ASCO GU22, ASCO21, AUA21, Cabozantinib, Carcinoma, Chronic kidney disease, Cryosurgery, EAU, EAU21, EAU22, EMUC21, EMUC22, ERUS22, ESMO21, Frail patient​, Glomerular filtration rate, Guidelines, IMDC risk model, Kidney cancer, Laparoscopy, Lymph node metastases, Lymph nodes, Metastasectomy, Mortality, Neoplasm metastasis, Neoplasm recurrence, Nephrectomy, Nephron-sparing surgery, Nivolumab, Overall survival, Partial nephrectomy, Prognostication, Radical nephrectomy, Radical surgery, RCC, Renal cancer, Renal cell, Renal cell carcinoma, Renal Cell Carcinoma guidelines, Renal cryoablation, Renal function, Renal Transplantation, Renorrhaphy, Robotic, Robotic prostatectomy, Robotic surgery, Survival outcome, Suture, Targeted therapies, Treatment response, Urological surgery, UROwebinar, Webinar
Show all

Three-dimensional model-assisted minimally invasive partial nephrectomy: A systematic review with meta-analysis of comparative studies

View

Oncological and peri-operative outcomes of percutaneous cryoablation of renal cell carcinoma for patients with hereditary RCC diseases – An analysis of European multi-centre prospective EuRECA registry

View

Is adjuvant immunotherapy worth for all patients with clear-cell renal cell carcinoma at high risk of recurrence?

View

Deciphering the relationship between pathogenic variants and clinical phenotype in VHL patients: results from a prospective observational study

View
webcasts

Development of an individual postoperative prediction model for kidney cancer recurrence using machine learning (UroCCR study 120)

View

Quality of life outcomes after robotic-assisted versus open partial nephrectomy: Results from the randomized ROBOCOP II trial

View

A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)

British Journal of Cancer, June 2022

View

Development and validation of a nomogram predicting intraoperative adverse events during robot-assisted partial nephrectomy

European Urology Focus, September 2022

View

A renewal of the TNM staging system for patients with renal cancer to comply with current decision-making: Proposal from the European Association of Urology guidelines panel

European Urology, October 2022

View

Stereotactic ablative radiation for systemic therapy–naïve oligometastatic kidney cancer

European Urology Oncology, August 2022

View

Phase II study of belzutifan plus cabozantinib as first-line treatment of advanced renal cell carcinoma (RCC): Cohort 1 of LITESPARK-003

, September 2022

View

Phase 2 KEYNOTE-B61 Study of Pembrolizumab (Pembro) + Lenvatinib (Lenva) as First-Line Treatment for Non-Clear Cell Renal Cell Carcinoma (nccRCC)

View
PreviousNext